Fig. 6

Lung cancer PDO-based high-throughput screening (HTS) and cancer organoid-based diagnosis reactivity prediction (CODRP) index analysis to alectinib. DRC-based drug response analysis using ALK-positive (A) and ALK-negative (B) patient-derived organoids to alectinib. (C) Comparative analysis of drug response based on the AUC and CODRP indices for alectinib; The CODRP index is calculated as a Z-score value based on different mean and standard deviation (SD) values of alectinib for individual PDO, considering the AUC index, cancer stage, and PDO growth rate through multiple linear regression (Mean, SD, and sample number of alectinib: 0.8, 0.36, 15). In the conventional AUC index-based analysis for the alectinib, the sensitivity was 100% and the specificity was 58.3%, but as a result of the CODRP index-based drug sensitivity analysis, the analysis performance improved to 100% sensitivity and 83.3% specificity